According to filings with the U.S. Securities and Exchange Commission, Scilex is raising $101,875,000.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Jaisim Shah played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Scilex
Scilex, a public majority-owned subsidiary of Sorrento located in Palo Alto, CA and San Diego, California, responsibly develops and brings branded pharmaceutical products to market using technologies designed to maximize quality of life. We are uncompromising in our focus to become the global pharmaceutical leader committed to social, environmental, economic, and ethical principles. Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., is an innovative revenue-generating company focused on acquiring, developing and commercialization of non-opioid pain management products for treatment of acute and chronic pain. Scilex is uncompromising in its focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life. Scilex is uncompromising in its focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life. Working together to make a difference in the world of pain management. The merger of Scilex and Semnur Pharmaceuticals creates a Global Leader in Non-Opioid Pain Management. Scilex Holding, Inc is 100% owner of Scilex Pharmaceuticals and Semnur Pharmaceuticals.

To learn more about Scilex, visit http://www.scilexholding.com/

Contact:
Jaisim Shah, President and Chief Executive Officer
650-516-4310

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.